ERBB2 and non-small cell lung carcinoma: Dacomitinib, an irreversible pan-HER TKI, was evaluated in a phase II trial in pretreated HER2-altered NSCLC patients and showed a 12% partial response rate in HER2-mutant patients, compared with 0% in those with HER2 amplification.